Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Here is ACIU news. Note: It slowed the

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Steady_T Member Profile
Member Level 
Followed By 130
Posts 16,239
Boards Moderated 2
Alias Born 12/09/04
160x600 placeholder
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 9/24/2021 5:05:26 PM
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/20/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today!  Register Now InvestorsHub NewsWire - 9/15/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference Today.  Register Now InvestorsHub NewsWire - 9/1/2021 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) GlobeNewswire Inc. - 8/26/2021 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/12/2021 5:13:54 PM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results GlobeNewswire Inc. - 8/12/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021 GlobeNewswire Inc. - 8/5/2021 7:00:00 AM
Steady_T Member Level  Tuesday, 08/31/21 10:47:15 AM
Re: Bourbon_on_my_cornflakes post# 328390
Post # of 338787 
Here is ACIU news. Note: It slowed the rate of decline and met one of two primary end points. Bolding is mine.

AC Immune SA on Tuesday said a Phase 2 study evaluating the safety and efficacy of its investigational anti-tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer's disease met one of its co-primary endpoints.

The Lausanne, Switzerland, clinical-stage biopharmaceutical company said semorinemab showed a statistically significant reduction in cognitive decline from baseline by 43.6% compared with placebo in the study. The study was being conducted by Roche Holding AG's Genentech unit, AC Immune's collaboration partner in Alzheimer's disease since 2006.

AC Immune said there was no effect on the other co-primary endpoint of reducing the rate of functional decline from baseline, adding that semorinemab was well tolerated in the study, with an acceptable safety profile and no unanticipated safety signals.

https://www.marketwatch.com/story/ac-immune-semorinemab-meets-co-primary-endpoint-in-alzheimer-s-disease-aciu-271630411441

If investing was easy, everyone would be rich by now.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences